ASPC Manual of Preventive Cardiology

Nathan D. Wong, PhD, FACC, FAHA, FASPC, FNLAProfessor and Director, Heart Disease Prevention ProgramDivision of Cardiology, University of California, IrvineAdjunct Professor of Epidemiology (UCLA and UC Irvine) and Population Sciences (UC Irvine)Past President, American Society for Preventive CardiologyC240 Medical SciencesIrvine, CA 92697-4079, USAT: 949-824-5561Email: ndwong@uci.edu  Ezra A. Amsterdam, MD, FACC, FAHADistinguished Professor of MedicineAssociate Chief, Division of Cardiovascular MedicinePast President, American Society for Preventive CardiologyDepartment of Internal MedicineUniversity of California (Davis) Medical Center4086 Y StreetSacramento, CA 95817, USAT: 916-734-5191Email: eaamsterdam@ucdmc.edu Peter P. Toth, MD, PhD, FAAFP, FCCP, FNLA, FASPC, FESC, FACCProfessor of Clinical Family and Community MedicineUniversity of Illinois School of MedicineAdjunct Associate Professor of MedicineCiccarone Center for Cardiovascular Disease Prevention, Johns Hopkins UniversityPresident, American Society for Preventive Cardiology101 East Miller RoadSterling, IL 61081, USAEmail: Peter.Toth@cghmc.com

• Chapter. 1: Focus on Cardiovascular Health Promotion and Disease Prevention- Opportunities for Improvement.- Chapter. 2: National and Global Trends of Cardiovascular Disease Mortality, Morbidity, and Risk.- Chapter. 3: Cardiovascular Risk Assessment: From Global Risk Scoring to Risk Enhancing Factors.- Chapter. 4: Assessment and Management of Psychosocial Risk Factors within Preventive Cardiology Practice.- Chapter. 5: Dietary Strategies for Atherosclerotic Cardiovascular Risk Reduction.- Chapter. 6: Physical Activity Strategies.- Chapter. 7: Obesity Management and Prevention of Cardiovascular Disease.- Chapter. 8: Smoking and Vaping.- Chapter. 9: Alcohol and Cardiovascular Diseases.- Chapter. 10: The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: A personalized approach to risk reduction.- Chapter. 11: Blood Pressure and Hypertension Management.- Chapter. 12: Cardiodiabetology: Reducing Risks to Optimize Cardiovascular Disease Outcomes.- Chapter. 13: Antiplatelet Therapy.- Chapter. 14: Inflammation and Atherosclerotic Cardiovascular Disease.- Chapter. 15: The Role of Genetics in Preventive Cardiology: Utility of Clinically Available Genetic Tests.- Chapter. 16: Exercise Electrocardiographic Stress Testing.- Chapter. 17: Ultrasound and MRI Assessment of Cardiovascular Risk.- Chapter. 18: Role of CT Coronary Calcium Scanning and Angiography in Evaluation of Cardiovascular Risk.- Chapter. 19: Cardiovascular Disease Prevention in Women.- Chapter. 20: Racial/Ethnic Considerations in the Prevention of Cardiovascular Disease.- Chapter. 21: Prevention of Heart Failure.- Chapter. 22: Prevention of Peripheral Arterial Disease.- Chapter. 23: Prevention of Atrial Fibrillation.- Chapter. 24: Prevention of Ischemic Stroke.- Chapter. 25: Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease.- Chapter. 26: Primary Prevention of Cardiovascular Disease Guidelines.- Chapter. 27: Secondary Prevention and Cardiac Rehabilitation.- Chapter. 28: Integrative Approaches for Cardiovascular Disease Prevention.- Chapter. 29: Preventive Cardiology as Specialized Medical Art.